| Biotechnology Industry | Healthcare Sector | Dr. Xiaoyi Li Ph.D. CEO | XFRA Exchange | KYG989M51017 ISIN |
| China Country | 297 Employees | - Last Dividend | - Last Split | - IPO Date |
Zhaoke Ophthalmology Limited is a leading ophthalmic pharmaceutical company dedicated to the research, development, and commercialization of innovative therapies that aim to meet unmet medical needs within the ophthalmology field in the People's Republic of China. The company, which was previously known as China Ophthalmology Focus Limited, has established its name in the industry since its inception in 2017. With its headquarters located in Guangzhou, Zhaoke Ophthalmology Limited focuses on bringing advanced treatment solutions for various eye diseases, leveraging its significant research and development capabilities to impact the ophthalmic care landscape positively.
As part of its mission to address the spectrum of eye health issues faced by patients, Zhaoke Ophthalmology Limited is renowned for its development of a wide range of drug candidates targeting critical ophthalmic conditions. These include: